智利某医院住院患者中2019冠状病毒病疫情期间抗生素消耗与产碳青霉烯酶肺炎克雷伯菌谱系出现:时间序列研究与系统发育基因组学分析
在智利圣地亚哥某三级医院2018至2022年间,比较新冠疫情前后静脉抗生素使用与耐碳青霉烯肠杆菌目频率,发现广谱β-内酰胺类、碳青霉烯类和黏菌素使用及产碳青霉烯酶菌株频率均显著增加,系统发育基因组学揭示产碳青霉烯酶耐碳青霉烯肺炎克雷伯菌新谱系ST45和ST1161的出现。
要点
- 疫情后广谱β-内酰胺类、碳青霉烯类和黏菌素使用量均较疫情前显著增加。
- 产碳青霉烯酶肠杆菌目频率从疫情前12.8%升至疫情后51.9%。
- 产碳青霉烯酶耐碳青霉烯肺炎克雷伯菌新谱系ST45和ST1161出现。
核心结论
- 新冠疫情后抗生素使用和产碳青霉烯酶肠杆菌目频率增加,产碳青霉烯酶耐碳青霉烯肺炎克雷伯菌的增加由新基因组谱系出现驱动。
研究设计与样本
- 在智利圣地亚哥某三级医院2018年至2022年间,分疫情前(2018年3月至2020年2月)和疫情后(2020年3月至2022年2月)两阶段,评估静脉抗生素使用和耐碳青霉烯肠杆菌目频率。
- 将月度抗生素使用量(定义为每1000患者日的限定日剂量)分为广谱β-内酰胺类、碳青霉烯类和黏菌素,采用中断时间序列分析比较疫情前后。
- 研究产碳青霉烯酶耐碳青霉烯肠杆菌目频率,并对研究期间收集的所有耐碳青霉烯肺炎克雷伯菌分离株进行全基因组测序分析。
主要发现
- 疫情后广谱β-内酰胺类使用量从疫情前78.1升至142.5限定日剂量/1000患者日(P < .001)。
- 疫情后碳青霉烯类使用量从疫情前50.9升至110.1限定日剂量/1000患者日(P < .001)。
- 疫情后黏菌素使用量从疫情前4.1升至13.3限定日剂量/1000患者日(P < .001)。
- 产碳青霉烯酶肠杆菌目频率从疫情前12.8%升至疫情后51.9%(P < .001)。
- 携带blaNDM的产碳青霉烯酶肠杆菌目从疫情前40%(n = 4/10)升至疫情后73.6%(n = 39/53)(P < .001)。
关键数值与推荐
- 两个时期中最常见的耐碳青霉烯肠杆菌目菌种均为耐碳青霉烯肺炎克雷伯菌(分别为79.5%和76.5%)。
- 系统发育基因组学分析揭示两个不同的产碳青霉烯酶耐碳青霉烯肺炎克雷伯菌基因组谱系出现:携带blaNDM的ST45和携带blaKPC的ST1161。
临床怎么用
- 作者指出观察结果强调需要加强感染预防与控制及抗菌药物管理措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) on antimicrobial use (AU) and resistance has not been well evaluated in South America. These data are critical to inform national policies and clinical care. METHODS: At a tertiary hospital in Santiago, Chile, between 2018 and 2022, subdivided into pre- (3/2018-2/2020) and post-COVID-19 onset (3/2020-2/2022), we evaluated intravenous AU and frequency of carbapenem-resistant Enterobacterales (CRE). We grouped monthly AU (defined daily doses [DDD]/1000 patient-days) into broad-spectrum β-lactams, carbapenems, and colistin and used interrupted time-series analysis to compare AU during pre- and post-pandemic onset. We studied the frequency of carbapenemase-producing (CP) CRE and performed whole-genome sequencing analyses of all carbapenem-resistant (CR) Klebsiella pneumoniae (CRKpn) isolates collected during the study period. RESULTS: Compared with pre-pandemic, AU (DDD/1000 patient-days) significantly increased after the pandemic onset, from 78.1 to 142.5 (P < .001), 50.9 to 110.1 (P < .001), and 4.1 to 13.3 (P < .001) for broad-spectrum β-lactams, carbapenems, and colistin, respectively. The frequency of CP-CRE increased from 12.8% pre-COVID-19 to 51.9% after pandemic onset (P < .001). The most frequent CRE species in both periods was CRKpn (79.5% and 76.5%, respectively). The expansion of CP-CRE harboring blaNDM was particularly noticeable, increasing from 40% (n = 4/10) before to 73.6% (n = 39/53) after pandemic onset (P < .001). Our phylogenomic analyses revealed the emergence of two distinct genomic lineages of CP-CRKpn: ST45, harboring blaNDM, and ST1161, which carried blaKPC. CONCLUSIONS: AU and the frequency of CP-CRE increased after COVID-19 onset. The increase in CP-CRKpn was driven by the emergence of novel genomic lineages. Our observations highlight the need to strengthen infection prevention and control and antimicrobial stewardship efforts.
引用
- Allel K, Peters A, Conejeros J, et al. Antibiotic Consumption During the Coronavirus Disease 2019 Pandemic and Emergence of Carbapenemase-Producing Klebsiella pneumoniae Lineages Among Inpatients in a Chilean Hospital: A Time-Series Study and Phylogenomic Analysis. Clin Infect Dis. 2023. PMID: 37406053. doi:10.1093/cid/ciad151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。